PARIS & CAMBRIDGE, England--(BUSINESS WIRE)--Novacyt (ALTERNEXT:ALNOV), an international specialist in cancer and infectious disease diagnostics, and Leica Biosystems, a leading supplier to the pathology market, have today signed an agreement where Leica Biosystems will have exclusive distribution of Novacyt’s NOVAPrep® cytology platform in Greater China markets. China is the fastest growing market for cervical cancer screening today. By 2020 it is expected to be significantly larger than the US market and will then be the number one market for liquid based cytology screening for the disease. There are estimated to be 60 million cervical cancer screening tests performed annually in China today and by 2020 this could grow to 150 million cervical cancer screening tests per year.
Help employers find you! Check out all the jobs and post your resume.
